NURIX THERAPEUTICS, INC. (NRIX) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-05-31..
Gross margin
Overview →Financial period ending 2026-05-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-05-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 36.77M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-05-31 | (m) | $36.77M | (m) | (m) |
| 2026-02-28 | (m) | $71.78M | (m) | (m) |
| 2025-11-30 | (m) | $83.98M | (m) | (m) |
| 2025-08-31 | (m) | $83.69M | (m) | (m) |
| 2025-05-31 | (m) | $88.38M | (m) | (m) |
| 2025-02-28 | (m) | $56.42M | (m) | (m) |
| 2024-11-30 | (m) | $54.55M | (m) | (m) |
| 2024-08-31 | (m) | $56.42M | (m) | (m) |
| 2024-05-31 | (m) | $62.30M | (m) | (m) |
| 2024-02-29 | (m) | $80.89M | (m) | (m) |
| 2023-11-30 | (m) | $76.99M | (m) | (m) |
| 2023-08-31 | (m) | $68.61M | (m) | (m) |
| 2023-05-31 | (m) | $60.94M | (m) | (m) |
| 2023-02-28 | (m) | $41.69M | (m) | (m) |
| 2022-11-30 | (m) | $38.63M | (m) | (m) |
| 2022-08-31 | (m) | $39.24M | (m) | (m) |
| 2022-05-31 | (m) | $38.70M | (m) | (m) |
| 2022-02-28 | (m) | $34.36M | (m) | (m) |
| 2021-11-30 | (m) | $29.75M | (m) | (m) |
| 2021-08-31 | (m) | $29.04M | (m) | (m) |
| 2021-05-31 | (m) | $22.88M | (m) | (m) |
| 2021-02-28 | (m) | $19.97M | (m) | (m) |
| 2020-11-30 | (m) | $17.82M | (m) | (m) |
| 2020-08-31 | (m) | $12.99M | (m) | (m) |
| 2020-05-31 | (m) | $19.49M | (m) | (m) |
| 2020-02-29 | (m) | $24.75M | (m) | (m) |
| 2019-11-30 | (m) | $31.11M | (m) | (m) |
| 2019-08-31 | (m) | (m) | (m) | (m) |
| 2019-05-31 | (m) | (m) | (m) | (m) |
| 2019-02-28 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |